CoChat

Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2–Restricted T Cell Epitopes

Open access
Hoppes, Rieuwert, Oostvogels, Rimke, Luimstra, Jolien J, Wals, Kim, Toebes, Mireille, Bies, Laura, Ekkebus, Reggy, Rijal, Pramila, Celie, Patrick H N, Huang, Julie H, Emmelot, Maarten E, Spaapen, Robbert M, Lokhorst, Henk, Schumacher, Ton N M, Mutis, Tuna, Rodenko, Boris, Ovaa, Huib · 2014 · The Journal of Immunology
Cited by 45

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Virus or tumor Ag–derived peptides that are displayed by MHC class I molecules are attractive starting points for vaccine development because they induce strong protective and therapeutic cytotoxic T cell responses. In thus study, we show that the MHC binding and consequent T cell reactivity against several HLA-A*02 restricted epitopes can be further improved through the incorporation of nonproteogenic amino acids at primary and secondary anchor positions. We screened more than 90 nonproteogenic, synthetic amino acids through a range of epitopes and tested more than 3000 chemically enhanced altered peptide ligands (CPLs) for binding affinity to HLA-A*0201. With this approach, we designed CPLs of viral epitopes, of melanoma-associated Ags, and of the minor histocompatibility Ag UTA2-1, which is currently being evaluated for its antileukemic activity in clinical dendritic cell vaccination trials. The crystal structure of one of the CPLs in complex with HLA-A*0201 revealed the molecular interactions likely responsible for improved binding. The best CPLs displayed enhanced affinity for MHC, increasing MHC stability and prolonging recognition by Ag-specific T cells and, most importantly, they induced accelerated expansion of antitumor T cell frequencies in vitro and in vivo as compared with the native epitope. Eventually, we were able to construct a toolbox of preferred nonproteogenic residues with which practically any given HLA-A*02 restricted epitope can be readily optimized. These CPLs could improve the therapeutic outcome of vaccination strategies or can be used for ex vivo enrichment and faster expansion of Ag-specific T cells for transfer into patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1400800

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 45

Metadata

Authors
Hoppes, R., Oostvogels, R., Luimstra, J. J., Wals, K., Toebes, M., Bies, L., Ekkebus, R., Rijal, P., Celie, P. H. N., Huang, J. H., Emmelot, M. E., Spaapen, R. M., Lokhorst, H., Schumacher, T. N. M., Mutis, T., Rodenko, B., & Ovaa, H.
Venue
The Journal of Immunology
Published
2014-11
Volume
193
Issue
10
Pages
4803-4813
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2157973715
Cited by
45
References
2
FWCI
1.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2–Restricted T Cell Epitopes. https://app.cochat.ai/papers/10.4049/jimmunol.1400800
The paper
Hoppes, R., Oostvogels, R., Luimstra, J. J., Wals, K., Toebes, M., Bies, L., Ekkebus, R., Rijal, P., Celie, P. H. N., Huang, J. H., Emmelot, M. E., Spaapen, R. M., Lokhorst, H., Schumacher, T. N. M., Mutis, T., Rodenko, B., & Ovaa, H. (2014). Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2–Restricted T Cell Epitopes. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1400800

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.